241 related articles for article (PubMed ID: 28445965)
1. Molecular docking, 3D-QSAR and structural optimization on imidazo-pyridine derivatives dually targeting AT1 and PPARg.
Zhang J; Hao QQ; Liu X; Jing Z; Jia WQ; Wang SQ; Xu WR; Cheng XC; Wang RL
Oncotarget; 2017 Apr; 8(15):25612-25627. PubMed ID: 28445965
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and evaluation of imidazo[4,5-c]pyridin-4-one derivatives with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-γ.
Casimiro-Garcia A; Heemstra RJ; Bigge CF; Chen J; Ciske FA; Davis JA; Ellis T; Esmaeil N; Flynn D; Han S; Jalaie M; Ohren JF; Powell NA
Bioorg Med Chem Lett; 2013 Feb; 23(3):767-72. PubMed ID: 23265881
[TBL] [Abstract][Full Text] [Related]
3. Identification of dual ligands targeting angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-γ by core hopping of telmisartan.
Zhang J; Liu X; Wang SQ; Liu GY; Xu WR; Cheng XC; Wang RL
J Biomol Struct Dyn; 2017 Sep; 35(12):2665-2680. PubMed ID: 27602589
[TBL] [Abstract][Full Text] [Related]
4. CoMFA and CoMSIA studies of angiotensin (AT1) receptor antagonists.
Datar P; Desai P; Coutinho E; Iyer K
J Mol Model; 2002 Oct; 8(10):290-301. PubMed ID: 12483229
[TBL] [Abstract][Full Text] [Related]
5. QSAR studies on 3-(4-biphenylmethyl) 4, 5-dihydro-4-oxo-3H-imidazo [4, 5-c] Pyridine derivatives as angiotensin II (AT1) receptor antagonist.
Sharma MC
Interdiscip Sci; 2015 Jun; 7(2):113-28. PubMed ID: 26215494
[TBL] [Abstract][Full Text] [Related]
6. Molecular Modeling Study for the Design of Novel Peroxisome Proliferator-Activated Receptor Gamma Agonists using 3D-QSAR and Molecular Docking.
Jian Y; He Y; Yang J; Han W; Zhai X; Zhao Y; Li Y
Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29473866
[TBL] [Abstract][Full Text] [Related]
7. Discovery of a series of imidazo[4,5-b]pyridines with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-γ.
Casimiro-Garcia A; Filzen GF; Flynn D; Bigge CF; Chen J; Davis JA; Dudley DA; Edmunds JJ; Esmaeil N; Geyer A; Heemstra RJ; Jalaie M; Ohren JF; Ostroski R; Ellis T; Schaum RP; Stoner C
J Med Chem; 2011 Jun; 54(12):4219-33. PubMed ID: 21557540
[TBL] [Abstract][Full Text] [Related]
8. Understanding electrostatic and steric requirements related to hypertensive action of AT(1) antagonists using molecular modeling techniques.
da C Silva D; Maltarollo VG; de Lima EF; Weber KC; Honorio KM
J Mol Model; 2014 Jul; 20(7):2231. PubMed ID: 24935104
[TBL] [Abstract][Full Text] [Related]
9. Probing the binding mechanism of substituted pyridine derivatives as effective and selective lysine-specific demethylase 1 inhibitors using 3D-QSAR, molecular docking and molecular dynamics simulations.
Wang ZZ; Yang J; Sun XD; Ma CY; Gao QB; Ding L; Liu HM
J Biomol Struct Dyn; 2019 Aug; 37(13):3482-3495. PubMed ID: 30175693
[TBL] [Abstract][Full Text] [Related]
10. Molecular modeling, quantum polarized ligand docking and structure-based 3D-QSAR analysis of the imidazole series as dual AT(1) and ET(A) receptor antagonists.
Singh KD; Muthusamy K
Acta Pharmacol Sin; 2013 Dec; 34(12):1592-606. PubMed ID: 24304920
[TBL] [Abstract][Full Text] [Related]
11. Development of docking-based 3D-QSAR models for PPARgamma full agonists.
Guasch L; Sala E; Valls C; Mulero M; Pujadas G; Garcia-Vallvé S
J Mol Graph Model; 2012 Jun; 36():1-9. PubMed ID: 22503857
[TBL] [Abstract][Full Text] [Related]
12. Computational investigation of imidazo[2,1-b]oxazole derivatives as potential mutant BRAF kinase inhibitors: 3D-QSAR, molecular docking, molecular dynamics simulation, and ADMETox studies.
Boutalaka M; El Bahi S; Alaqarbeh M; El Alaouy MA; Koubi Y; Khatabi KE; Maghat H; Bouachrine M; Lakhlifi T
J Biomol Struct Dyn; 2024 Jul; 42(10):5268-5287. PubMed ID: 37424193
[TBL] [Abstract][Full Text] [Related]
13. Molecular modelling studies for the discovery of new substituted pyridines derivatives with angiotensin II AT1 receptor antagonists.
Sharma MC
Interdiscip Sci; 2014 Sep; 6(3):197-207. PubMed ID: 25205497
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, pharmacological evaluation and in silico ADMET prediction of novel substituted benzimidazole derivatives as angiotensin II-AT1 receptor antagonists based on predictive 3D QSAR models.
Vyas VK; Gupta N; Ghate M; Patel S
SAR QSAR Environ Res; 2014; 25(2):117-46. PubMed ID: 24598006
[TBL] [Abstract][Full Text] [Related]
15. Virtual identification of novel PPARα/γ dual agonists by 3D-QSAR, molecule docking and molecular dynamics studies.
Liu YY; Feng XY; Jia WQ; Jing Z; Xu WR; Cheng XC
J Biomol Struct Dyn; 2020 Jun; 38(9):2672-2685. PubMed ID: 31418313
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and docking studies of novel benzimidazoles for the treatment of metabolic syndrome.
Mizuno CS; Chittiboyina AG; Shah FH; Patny A; Kurtz TW; Pershadsingh HA; Speth RC; Karamyan VT; Carvalho PB; Avery MA
J Med Chem; 2010 Feb; 53(3):1076-85. PubMed ID: 20073471
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and evaluation of new designed multiple ligands directed towards both peroxisome proliferator-activated receptor-γ and angiotensin II type 1 receptor.
Meyer M; Foulquier S; Dupuis F; Flament S; Grimaud L; Henrion D; Lartaud I; Monard G; Grillier-Vuissoz I; Boisbrun M
Eur J Med Chem; 2018 Oct; 158():334-352. PubMed ID: 30223121
[TBL] [Abstract][Full Text] [Related]
18. 3D QSAR studies on peroxisome proliferator-activated receptor gamma agonists using CoMFA and CoMSIA.
Liao C; Xie A; Zhou J; Shi L; Li Z; Lu XP
J Mol Model; 2004 Jun; 10(3):165-77. PubMed ID: 15022104
[TBL] [Abstract][Full Text] [Related]
19. The discovery of new potent non-peptide Angiotensin II AT1 receptor blockers: a concise synthesis, molecular docking studies and biological evaluation of N-substituted 5-butylimidazole derivatives.
Agelis G; Resvani A; Durdagi S; Spyridaki K; Tůmová T; Slaninová J; Giannopoulos P; Vlahakos D; Liapakis G; Mavromoustakos T; Matsoukas J
Eur J Med Chem; 2012 Sep; 55():358-74. PubMed ID: 22889560
[TBL] [Abstract][Full Text] [Related]
20. Proposal of a new binding orientation for non-peptide AT1 antagonists: homology modeling, docking and three-dimensional quantitative structure-activity relationship analysis.
Tuccinardi T; Calderone V; Rapposelli S; Martinelli A
J Med Chem; 2006 Jul; 49(14):4305-16. PubMed ID: 16821790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]